FDA to Decide on Bydureon on Jan 28, 2012

More Diabetes In Control Aug 16, 2011, 3:58 am

The FDA is expected to make a decision Jan. 28 on the once-weekly diabetes drug Bydureon by Eli Lilly and Amylin. Amylin and its partners Eli Lilly and Co., and Alkermes, Inc., said the FDA has accepted their approval resubmission and set an action date of Jan. 28 for the drug Bydureon, the proposed brand name for the exenatide extended-release injectable treatment. It has already been approved in Europe. FDA … Read the Rest

Tags: bydureon, amylin, lilly, drug,

Page Information

  • Keywords: diabetes, diabetes newsletter, diabetic newsletter, diabetes, news for diabetics, news for doctors, diabetes in children, diabetes in control,
    health, blood sugars, diabetes type 1, diabetes type 2, health care, blood sugars, low blood sugars, lower blood sugars, a1cnow, hba1c, hemoglobin a1c, sportbrain,
    tacticon, diabetes care, pharmacy
  • Description: Diabetes In Control is a free weekly diabetes newsletter dedicated to helping medical professionals in diabetes care better
    help their diabetes patients.